-+ 0.00%
-+ 0.00%
-+ 0.00%

Laikai Pharmaceutical-B announced that the Group has successfully completed a phase I single-dose escalation study of LAE103 in overweight or obese subjects in Australia. The SAD study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic properties of LAE103 in overweight or obese subjects.

Zhitongcaijing·11/09/2026 01:09:04
Listen to the news
Laikai Pharmaceutical-B announced that the Group has successfully completed a phase I single-dose escalation study of LAE103 in overweight or obese subjects in Australia. The SAD study was a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic properties of LAE103 in overweight or obese subjects.